Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study

Histology and Histopathology

Volumn 28, Issue 1, 2013, Pages 133-144

  Muñoz Repeto, Iván ^a,j   García, María José ^a,j   Kamieniak, Marta ^a   Ramón y Caja, Teresa ^b   Domingo, Samuel ^a   Cazorla, Alicia ^c   Donas, Jesús García ^d   Polo, Susana Hernando ^d   Sagredo, José Miguel García ^e   Hernández, Elena ^a   Lacambra, Carmen ^f   Saez, Raquel ^g   Robles, Luis ^h   Borrego, Salud ^i,j   Prat, Jaime ^b   Palacios, José ⁱ   Benítez, Javier ^a,j  

^a Structural Biology and Biocomputing Programme   (Spain)

^b Hospital Sant Pau   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL SEVERO OCHOA   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

more..

Author keywords

Epithelial ovarian cancer; Hereditary; Immunohistochemistry

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; PHENOTYPE; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; TISSUE ARRAY ANALYSIS;

EID: 84872170912     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Aida H., Takakuwa K., Nagata H., Tsuneki I., Takano M., Tsuji S., Takahashi T., Sonoda T., Hatae M., Takahashi K., Hasegawa K., Mizunuma H., Toyoda N., Kamata H., Torii Y., Saito N., Tanaka K., Yakushiji M. and Araki T. (1998). Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res. 4, 235-240.
2. Anttila M., Kosma V.M., Ji H., Wei-Ling X., Puolakka J., Juhola M., Saarikoski S. and Syrjanen K. (1998). Clinical significance of alphacatenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J. Clin. Oncol. 16, 2591-2600.
3. Auersperg N., Wong A.S., Choi K.C., Kang S.K. and Leung P.C. (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255-288.
4. Berchuck A., Heron K.A., Carney M.E., Lancaster J.M., Fraser E.G., Vinson V.L., Deffenbaugh A.M., Miron A., Marks J.R., Futreal P.A. and Frank T.S. (1998). Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin. Cancer Res. 4, 2433-2437.
5. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., Saigo P.E., Almadrones L.A., Barakat R.R., Brown C.L., Chi D.S., Curtin J.P., Poynor E.A. and Hoskins W.J. (2000). Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283, 2260-2265.
6. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L. and Montz F.J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J. Clin. Oncol. 20, 1248-1259.
7. Brun J.L., Cortez A., Commo F., Uzan S., Rouzier R. and Darai E. (2008). Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int. J. Oncol. 33, 1239-1246.
8. Cannistra S.A. (2004). Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529.
9. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A. and Karlan B.Y. (2003). Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187-2195.
10. Garcia M.J., Fernandez V., Osorio A., Barroso A., Fernandez F., Urioste M. and Benitez J. (2009). Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis 30, 1898-1902.
11. Hanna L. and Adams M. (2006). Prevention of ovarian cancer. Best practice & research. Clin. Obst. Gynaecol. 20, 339-362.
12. Histological typing of ovarian tumours. (2004). In: International Histological Classification of Tumours, World Health Organization, Scully R. (ed). Springer. Berlin. pp 11-19.
13. Honrado E., Osorio A., Palacios J., Milne R.L., Sanchez L., Diez O., Cazorla A., Syrjakoski K., Huntsman D., Heikkila P., Lerma E., Kallioniemi A., Rivas C., Foulkes W.D., Nevanlinna H. and Benitez J. (2005). Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J. Clin. Oncol. 23, 7503-7511.
14. Kaern J., Aghmesheh M., Nesland J.M., Danielsen H.E., Sandstad B., Friedlander M. and Trope C. (2005). Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int. J. Gynecol. Cancer 15, 1014-1022.
15. Lakhani S.R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., McGuffog L., Steele D., Devilee P., Klijn J.G., Meijers-Heijboer H., Radice P., Pilotti S., Nevanlinna H., Butzow R., Sobol H., Jacquemier J., Lyonet D.S., Neuhausen S.L., Weber B., Wagner T., Winqvist R., Bignon Y.J., Monti F., Schmitt F., Lenoir G., Seitz S., Hamman U., Pharoah P., Lane G., Ponder B., Bishop D.T. and Easton D.F. (2004). Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 10, 2473-2481.
16. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L. and Hung M.C. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3, 802-808.
17. Milne R.L., Osorio A., Cajal T.R., Vega A., Llort G., de la Hoya M., Diez O., Alonso M.C., Lazaro C., Blanco I., Sanchez-de-Abajo A., Caldes T., Blanco A., Grana B., Duran M., Velasco E., Chirivella I., Cardenosa E.E., Tejada M.I., Beristain E., Miramar M.D., Calvo M.T., Martinez E., Guillen C., Salazar R., San Roman C., Antoniou A.C., Urioste M. and Benitez J. (2008). The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin. Cancer Res. 14, 2861-2869.
18. Miller A.B., Hoogstraten B., Staquet M. and Winkler A. (1981). Reporting results of cancer treatment. Cancer 47, 207-214.
19. Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., Pujade-Lauraine E., Lisyanskaya A.S., Makhson A.N., Rolski J., Gorbounova V.A., Ghatage P., Bidzinski M., Shen K., Ngan H.Y., Vergote I.B., Nam J.H., Park Y.C., Lebedinsky C.A. and Poveda A.M. (2010). Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28, 3107-3114.
20. Morrissey E.R. and Diaz-Uriarte R. (2009). Pomelo II: finding differentially expressed genes. Nucleic Acids Res. 37, W581-W586.
21. Ni X., Zhang W., Huang K.C., Wang Y., Ng S.K., Mok S.C., Berkowitz R.S. and Ng S.W. (2004). Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br. J. Cancer 91, 725-731.
22. Palacios J., Honrado E., Osorio A., Cazorla A., Sarrio D., Barroso A., Rodriguez S., Cigudosa J.C., Diez O., Alonso C., Lerma E., Sanchez L., Rivas C. and Benitez J. (2003). Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 9, 3606-3614.
23. Piver M.S. (2002). Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol. Oncol. 85, 9-17.
24. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A. and Taddei G.L. (2004). Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol. Oncol. 92, 806-812.
25. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., Morgan M.A., LiVolsi V.A., Berchuck A., Muto M.G., Garber J.E., Weber B.L., Lynch H.T. and Boyd J. (1996). Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Me. 335, 1413-1416.
26. Schmandt R.E., Broaddus R., Lu K.H., Shvartsman H., Thornton A., Malpica A., Sun C., Bodurka D.C. and Gershenson D.M. (2003). Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98, 758-764.
27. Schoffski P., Taron M., Jimeno J., Grosso F., Sanfilipio R., Casali P.G., Le Cesne A., Jones R.L., Blay J.Y., Poveda A., Maki R.G., Nieto A., Tercero J.C. and Rosell R. (2011). Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur. J. Cancer 47, 1006-1012.
28. Silverberg S.G. (2000). Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19, 7-15.
29. Smyth G.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3.
30. Steffensen K.D., Waldstrom M. and Jakobsen A. (2009). The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int. J. Gynecol. Cancer 19, 820-825.
31. Stratton J.F., Pharoah P., Smith S.K., Easton D. and Ponder B.A. (1998). A systematic review and meta-analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 105, 493-499.
32. Tagliaferri P., Ventura M., Baudi F., Cucinotto I., Arbitrio M., Di Martino M.T. and Tassone P. (2009). BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? J. Ovarian Res. 2, 14.
33. Tangjitgamol S., Manusirivithaya S., Khunnarong J., Jesadapatarakul S. and Tanwanich S. (2009). Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int. J. Gynecol. Cancer 19, 620-627.
34. Voutilainen K.A., Anttila M.A., Sillanpaa S.M., Ropponen K.M., Saarikoski S.V., Juhola M.T. and Kosma V.M. (2006). Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J. Clin. Pathol. 59, 460-467.
35. Werness B.A. and Eltabbakh G.H. (2001). Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. Int. J. Gynecol. Pathol. 20, 48-63.
36. Xia W., Wei Y., Du Y., Liu J., Chang B., Yu Y.L., Huo L.F., Miller S. and Hung M.C. (2009). Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol. Carcinog. 48, 610-617.